Prelude Therapeutics (PRLD) Stock Price, Quote, News & History | Benzinga

Prelude Therapeutics Inc (PRLD) Stock Price, Quote, News & History

PRLDNASDAQ

Trade with Public

Trade with Public

$6.63

0.132%

At close: Aug 21, 5:00 PM EST

$6.69

0.060.9%

After Hours: Aug 21, 7:32 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$6.56

Close

$6.63

Volume / Avg.

519.21K / 453.36K

Day Range

$6.40 - $6.82

52 Wk Range

0.85 - 6.65

Market Cap

$533.89M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

76

Short Interest

14.5%

Days to Cover

9.31

Recent Prelude Therapeutics Incorporated News

Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.

Avi Kapoor

Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market trading

Avi Kapoor

Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmark, HC Wainwright, Stifel, B of A Sec, Mizuho updated their ratings and price targets.

Avi Kapoor

Dow Dips Over 400 Points; Pfizer Earnings Top Estimates

Avi Kapoor

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-33.26M

Investing Cash Flow (TTM)

-77.25M

Financing Cash Flow (TTM)

110.45M

Free Cash Flow (TTM)

-33.26M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-62.00K

Analyst Trends and Forecast

0

0

0

0

Mar

1

Apr

1

May

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$394.19M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

24.37

PB Ratio (TTM)

3.87

Earnings Yield % (TTM)

-11.25%

Earnings Yield % (FWD)

-9.55%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.68

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

$0

Total Cash

$26.33M

Debt to Equity

0.13

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

$0

Key Statistics

Open

$6.56

Close

$6.63

Volume / Avg.

519.21K / 453.36K

Day Range

$6.40 - $6.82

52 Wk Range

0.85 - 6.65

Market Cap

$533.89M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

76

Short Interest

14.5%

Days to Cover

9.31

About

Sector

Health Care

Industry

Biotechnology

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinica...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Prelude Therapeutics (PRLD) stock?

A

You can purchase shares of Prelude Therapeutics (NASDAQ:PRLD) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Prelude Therapeutics (PRLD) competitors?

A

Other companies in Prelude Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Prelude Therapeutics (PRLD) stock?

A

Prelude Therapeutics has a consensus price target of $5.43.

Q

What is the current price for Prelude Therapeutics (PRLD)?

A

The stock price for Prelude Therapeutics (NASDAQ: PRLD) is $6.69 last updated August 21, 2026 at 7:32 PM EDT.

Q

Does Prelude Therapeutics (PRLD) pay a dividend?

A

There are no upcoming dividends for Prelude Therapeutics.

Q

When is Prelude Therapeutics (NASDAQ:PRLD) reporting earnings?

A

Prelude Therapeutics does not have any upcoming earnings scheduled.

Q

Is Prelude Therapeutics (PRLD) going to split?

A

There is no upcoming split for Prelude Therapeutics.

Q

What sector and industry does Prelude Therapeutics (PRLD) operate in?

A

Prelude Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.